Delivery Order SPE2DB22D1017-SPE2DB25FYNYV
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of CellCept 500 mg tablets (100-count units) valued at $7,015.33. This firm fixed-price delivery order, with an ultimate completion date of August 5, 2025, represents a non-set-aside competitive award supporting federal pharmaceutical procurement needs. The product will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $12,986.33 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (500 count) on August 11, 2025, with completion scheduled for August 12, 2025. This firm fixed price, competitively awarded delivery order represents a single pharmaceutical product shipment with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is performing the...
- The Defense Logistics Agency awarded a delivery order valued at $2,545.90 to AmerisourceBergen Drug Corp for 100 tablets of CellCept 500 mg on September 3, 2025, with an ultimate completion date of September 4, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order through its Corporate Office division as part of ongoing...
- The Defense Logistics Agency awarded a delivery order valued at $35,063.75 to AmerisourceBergen Drug Corp for 100 tablets of CellCept 500 mg, with an ultimate completion date of July 28, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a delivery order under a larger contract vehicle. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency awarded a delivery order valued at $12,027.50 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (500-count) on August 7, 2025, with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and specifies performance at the contractor's facility in Conshohocken, Pennsylvania. CellCept (mycophenolate mofetil) is an immunosuppressant medication used to prevent organ...
- The Defense Logistics Agency awarded a delivery order valued at $9,024.78 to AmerisourceBergen Drug Corp for CellCept 500 mg tablets (100-count units) on August 4, 2025, with an ultimate completion date of August 5, 2025. This firm fixed price delivery order represents a non-competitive set-aside and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. CellCept (mycophenolate mofetil) is an immunosuppressant medication commonly used in military and...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,224.16 firm fixed-price delivery order is for the supply of 4,567,390,794 units of CELLCEPT 500 MG TABLET 100S, a pharmaceutical product. The contract has an ultimate completion date of February 27, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This is a delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA), a defense agency. The order is for CELLCEPT 500 MG TABLET 500S, a pharmaceutical product, and has a ceiling value of $9,699.50. The contract is a Firm Fixed Price delivery order with a completion date of June 4, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support...
- This is a $55,214.59 firm fixed-price delivery order contract awarded to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA) for CELLCEPT 500 MG TABLET 500S. The contract has an ultimate completion date of June 17, 2025. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, providing a comprehensive global pharmaceutical support...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $12,036.59, is for the delivery of CELLCEPT 500 MG TABLET 500S, a pharmaceutical product, with a completion date of May 20, 2025. The award is not set aside and involves open competition. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC)...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FYNYVDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of CellCept 500 mg tablets (100-count packages) under a firm fixed-price contract valued at $4,349.15. This is a non-set-aside competitive award with an ultimate completion date of August 26, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a comprehensive pharmaceutical prime vendor contract valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal military and veteran healthcare systems through this prime vendor vehicle, which enables the company to supply a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs globally. The DLA awards delivery orders against this IDC to meet specific pharmaceutical needs across the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. CellCept is an immunosuppressant medication used in transplant and autoimmune disease management, reflecting the scope of specialty pharmaceuticals distributed through this contract to support military medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 8/25/25 |